About 800 reports

China’s demand for Lymphoma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...

  • Lymphoma
  • China
  • Prescription Drug Sales
  • Industrial Production

The Global T-Cell Lymphoma Market was valued at USD 1,547.04 million in 2020, and it is expected to reach USD 2509.94 million by 2026, registering a CAGR of 8.25% during the period of 2021-2026. Due to the high transmission rate of COVID_19 and lack of treatment, many countries suffered, and they are continuing to bear a significant...

  • Lymphoma
  • APAC
  • Europe
  • North America
  • Africa
  • Health Expenditure
  • Stem Cell Transplantation

T-Cell Lymphomas - Epidemiology Forecast to 2030 Summary TCL are a rare type of cancer that form in T-cells and are either indolent (slow-growing) or aggressive.TCL either develops in lymphoid tissues such as the lymph nodes and spleen, or in other organs (gastrointestinal tract, liver, nasal cavity,...

  • Lymphoma
  • Immunotherapy
  • Epidemiology
  • China
  • Germany
  • World
  • Japan
  • France
  • Italy
  • Spain
  • Cancer Incidence
  • Urban Population

“Global Lymphoma Antibodies Market & Clinical Trials Insight 2028” Report Highlights: • Global Lymphoma Antibodies Market Opportunity: >USD 6 Billion • Global Lymphoma Antibodies Market Insights: Current, Regional & Future Outlook 2028 • Annual, Quarterly & Regional Sales Insights On Lymphoma Antibodies • Lymphoma...

  • Lymphoma
  • World

Abstract: - Global Lymphoma Therapeutics Market to Reach $23.6 Billion by 2027 - Amid the COVID-19 crisis, the global market for Lymphoma Therapeutics estimated at US$14.9 Billion in the year 2020, is projected to reach a revised size of US$23.6 Billion by 2027, growing at aCAGR of 6.8% over the period 2020-2027....

  • Lymphoma
  • World
  • China
  • United States

Global BCL-2 (B-cell Lymphoma 2) Inhibitors Market 2022-2026 The analyst has been monitoring the BCL-2 (B-cell Lymphoma 2) inhibitors market and it is poised to grow by $ 1.43 bn during 2022-2026, progressing at a CAGR of 12.60% during the forecast period. Our report on the BCL-2 (B-cell Lymphoma 2) inhibitors market provides...

  • Lymphoma
  • World

Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2022-2026 The analyst has been monitoring the diffuse large B-cell lymphoma (DLBCL) therapeutics market and it is poised to grow by $ 1.79 bn during 2022-2026 progressing at a CAGR of 7.71% during the forecast period. Our report on the diffuse large B-cell...

  • Lymphoma
  • Therapy
  • World

Abstract: - Global Non-Hodgkin Lymphoma Therapeutics Market to Reach $8.1 Billion  by 2027 - Amid the COVID-19 crisis, the global market for Non-Hodgkin Lymphoma Therapeutics estimated at US$5.4 Billion  in the year 2020, is projected to reach a revised size of US$8.1 Billion  by 2027, growing at a CAGR of 6% over...

  • Lymphoma
  • Therapy
  • World
  • China
  • United States

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021 Summary Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021 provides an overview...

  • Lymphoma
  • World

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) - Drugs in Development, 2021 Summary Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase...

  • Lymphoma
  • World

B Cell Lymphoma/Leukemia 11A (B Cell CLL/Lymphoma 11A or COUP TF Interacting Protein 1 or Ecotropic Viral Integration Site 9 Protein Homolog or Zinc Finger Protein 856 or BCL11A) - Drugs in Development, 2021 Summary B Cell Lymphoma/Leukemia 11A (B Cell CLL/Lymphoma 11A or COUP TF Interacting Protein...

  • Lymphoma
  • Immunotherapy
  • World

The global lymphoma treatment market grew at a CAGR of around 8% during 2015-2020. Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow...

  • Lymphoma
  • World
  • Diagnostic Imaging Density

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2021-2025 The analyst has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 3.43 billion during 2021-2025, progressing at a CAGR of almost 22% during the forecast period. Our report on anaplastic lymphoma kinase...

  • Lymphoma
  • World

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 Summary Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under...

  • Lymphoma
  • Therapy
  • Research And Development
  • World

Burkitt Lymphoma (Oncology) - Drugs in Development, 2021 Summary Burkitt Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Burkitt Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma,...

  • Lymphoma
  • World

Follicular Lymphoma (Oncology) - Drugs in Development, 2021 Summary Follicular Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Follicular Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Follicular...

  • Lymphoma
  • World

Mantle Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Mantle Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Mantle Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mantle...

  • Lymphoma
  • World

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) (Oncology) - Drugs in Development, 2021 Summary Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) (Oncology) - Drugs in Development, 2021 provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline...

  • Cancer
  • Lymphoma
  • World

Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 Summary Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for...

  • Lymphoma
  • Therapy
  • Research And Development
  • World

Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021 Summary Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021 provides an overview of the Natural Killer Cell Lymphomas pipeline landscape. The report provides comprehensive information on the therapeutics...

  • Cell Therapy
  • Lymphoma
  • World

Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021 Summary Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021 provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Splenic Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Splenic Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Nodal Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Nodal Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Nodal Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Marginal Zone B-cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Marginal Zone B-cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics...

  • Lymphoma
  • World

B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 Summary B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 provides in depth analysis on B Cell Lymphoma 2 (Bcl 2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage...

  • Lymphoma
  • World

Histone Deacetylase 3 - Pipeline Review, H2 2020 Summary Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest...

  • Lymphoma
  • Pharmaceutical
  • Biotechnology
  • World
  • Pharmaceutical Registrations
  • Diagnostic Imaging Density

Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 Summary Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis...

  • Lymphoma
  • Research And Development
  • Drug Development
  • World

ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 Summary ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on ALK Tyrosine Kinase Receptor...

  • Lymphoma
  • Research And Development
  • Drug Development
  • World

G1/S Specific Cyclin D1 (B Cell Lymphoma 1 Protein or BCL 1 Oncogene or PRAD1 Oncogene or CCND1) - Drugs in Development, 2021 Summary G1/S Specific Cyclin D1 (B Cell Lymphoma 1 Protein or BCL 1 Oncogene or PRAD1 Oncogene or CCND1) - Drugs in Development, 2021 provides in depth analysis on G1/S Specific...

  • Lymphoma
  • World